LUPIN LIMITED

SAFETY DATA SHEET

Section 1: Identification

Section 1, Identification

Material KAITLIB Fe

Norethindrone and Ethinyl Estradiol Chewable Tablets

(0.8 mg/0.025mg) Ferrous Fumarate Chewable Tablets

Manufacturer Lupin Limited

Pithampur (M.P.) - 454 775

India

Distributor Lupin Pharmaceuticals, Inc.

111 South Calvert Street, Harborplace Tower, 21st Floor, Baltimore, Maryland 21202

United States

Tel. 001-410-576-2000 Fax. 001-410-576-2221

Section 2: Hazard(s) Identification

Section 2, Hazard(s) identification

Fire and Explosion

Expected to be non-combustible.

Health

Do not prescribe Kaitlib Fe to women who are known to have the following:

- A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:
 - Smoke, if over age 35
 - Have deep vein thrombosis or pulmonary embolism, now or in the past
 - Have cerebrovascular disease
 - Have coronary artery disease
 - ❖ Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)
 - Have inherited or acquired hypercoagulopathies
 - Have uncontrolled hypertension
 - Have diabetes with vascular disease
 - Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35
- Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past

SDS : 127/01 Page 1 of 5

- Liver tumors, benign or malignant, or liver disease
- Undiagnosed abnormal uterine bleeding
- Pregnancy, because there is no reason to use COCs during pregnancy

Environment

No information is available about the potential of this product to produce adverse environmental effects.

Section 3: Composition/Information on Ingredients

Section 3, Composition/information on ingredients

Ingredients CAS

Norethindrone USP 68-22-4
Ethinyl Estradiol 57-63-6

Section 4: First-Aid Measures

Section 4, First-aid measures

Ingestion If conscious, give water to drink and induce vomiting. Do not attempt

to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water.

Obtain medical attention.

Inhalation Move individual to fresh air. Obtain medical attention if breathing

difficulty occurs. If not breathing, provide artificial respiration

assistance.

Skin Contact Remove contaminated clothing and flush exposed area with large

amounts of water. Wash all exposed areas of skin with plenty of soap

and water. Obtain medical attention if skin reaction occurs.

Eye Contact Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment Treat according to locally accepted protocols. For additional

guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum

electrolytes, etc.

OVERDOSAGE There have been no reports of serious ill effects from overdose of

oral contraceptives including ingestion by children. Overdosage may

cause nausea, and withdrawal bleeding may occur in females.

Section 5: Fire-Fighting Measures

Section 5, Fire-fighting measures

Fire and Explosion Hazards Assume that this product is capable of sustaining combustion.

Extinguishing Media Water spray, carbon dioxide, dry chemical powder or appropriate

foam.

Special Firefighting Procedures For single units (packages): No special requirements needed.

For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended

for firefighters.

Hazardous Combustion Products Hazardous combustion or decomposition products are expected

when the product is exposed to fire.

Section 6: Accidental Release Measures

Section 6, Accidental release measures

Personal Precautions Wear protective clothing and equipment consistent with the degree of

hazard.

Environmental Precautions For large spills, take precautions to prevent entry into waterways,

sewers, or surface drainage systems.

Clean-up Methods Collect and place it in a suitable, properly labeled container for

recovery or disposal.

Section 7: Handling and Storage

Section 7, Handling and storage

Handling No special control measures required for the normal handling of this

product.

Normal room ventilation is expected to be adequate for routine

handling of this product.

Storage Store at 25°C (77°F); excursions permitted to 15° to 30°C

(59° to 86°F) [see USP Controlled Room Temperature]. Keep this drug and all drugs out of the reach of children.

Section 8: Exposure Controls/Personal Protection

Section 8, Exposure controls/personal protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

SDS : 127/01 Page 3 of 5 Effective Date : 05/11/2015

Section 9: Physical and Chemical Properties

Section 9, Physical and chemical properties

Physical Form

Kaitlib Fe (norethindrone and ethinyl estradiol chewable tablets and ferrous fumarate chewable tablets) is available in a wallet containing 28 tablets (NDC 68180-903-11). Each wallet is packed in a pouch (NDC 68180-903-11) and three such pouches are packed in a carton (NDC 68180-903-13).

Each wallet (28 tablets) contains in the following order:

- 24 light green, round flat face beveled edged tablets (active) debossed with "I61" on one side and "LU" on the other side each containing 0.8 mg norethindrone and 0.025 mg ethinyl estradiol.
- 4 brown mottled, round, flat face beveled edge tablets (non-hormonal placebo) debossed with "LU" on one side and "I62" on the other side and each containing 75 mg ferrous fumarate.

Section 10: Stability and Reactivity

Section 10, Stability and reactivity

Stable under recommended storage conditions.

Section 11: Toxicological Information

Section 11, Toxicological information

Carcinoma of the Breasts and Reproductive Organs

Women who currently have or have had breast cancer should not use Kaitlib Fe because breast cancer is a hormonally-sensitive tumor.

There is substantial evidence that COCs do not increase the incidence of breast cancer. Although some past studies have suggested that COCs might increase the incidence of breast cancer, more recent studies have not confirmed such findings.

Some studies suggest that COCs are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there is controversy about the extent to which these findings may be due to differences in sexual behavior and other factors.

Section 12: Ecological Information

Section 12: Ecological Information

No relevant studies identified.

SDS : 127/01 Page 4 of 5

Section 13: Disposal Considerations

Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

Section 14: Transport Information

Section 14: Transport Information

IATA/ICAO - Not Regulated

IATA Proper shipping Name : N/A
IATA UN/ID No : N/A
IATA Hazard Class : N/A
IATA Packaging Group : N/A
IATA Label : N/A

IMDG - Not Regulated

IMDG Proper shipping Name:N/AIMDG UN/ID No:N/AIMDG Hazard Class:N/AIMDG Flash Point:N/AIMDG Label:N/A

DOT - Not Regulated

DOT Proper shipping Name : N/A
DOT UN/ID No : N/A
DOT Hazard Class : N/A
DOT Flash Point : N/A
DOT Packing Group : N/A
DOT Label : N/A

Section 15: Regulatory Information

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this MSDS.

SDS : 127/01 Page 5 of 5